Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody-Drug Conjugate.
Groothuis PG, Jacobs DCH, Hermens IAT, Damming D, Berentsen K, Mattaar-Hepp E, Stokman MEM, Boekel TV, Rouwette M, van der Vleuten MAJ, Sesink A, Dijcks FA, Coumans RGE, Schouten J, Glaudemans DH, Wijk DV, Blomenröhr M, Kappers WA, Ubink R, van der Lee MMC, Dokter WHA.
Groothuis PG, et al. Among authors: jacobs dch.
Mol Cancer Ther. 2023 Jun 1;22(6):765-777. doi: 10.1158/1535-7163.MCT-22-0596.
Mol Cancer Ther. 2023.
PMID: 37042205
Free PMC article.